help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bitton, R.
Right arrow Articles by Schneider, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bitton, R.
Right arrow Articles by Schneider, B. S.

Journal of Clinical Endocrinology & Metabolism, Vol 77, 1423-1426, Copyright © 1993 by Endocrine Society

ARTICLES

Leukemia after a small dose of radioiodine for metastatic thyroid cancer

R Bitton, I Sachmechi, Y Benegalrao and BS Schneider
Division of Endocrinology, Long Island Jewish Medical Center, New Hyde Park, New York 11042.

Radioiodine is widely used in the treatment of thyroid cancer. It is one of the most benign forms of therapy for malignancy. Leukemia is a rare complication of 131I therapy, usually occurring after cumulative dosages of more than 800 mCi and with intervals between doses of less than 12 months. We report the occurrence of acute myelogenous leukemia in a 28-yr-old woman 14 months after receiving a total dose of 300 mCi 131I for metastatic follicular thyroid cancer. We also review the published literature of the incidence of leukemia after low dose 131I.


This article has been cited by other articles:


Home page
 haematolHome page
D. Focosi, S. Galimberti, and M. Petrini
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases
Haematologica, September 1, 2007; 92(9): e96 - e97.
[Full Text] [PDF]

Home page
 BloodHome page
J. M. Bennett, M. S. Kaminski, J. P. Leonard, J. M. Vose, A. D. Zelenetz, S. J. Knox, S. Horning, O. W. Press, J. A. Radford, S. M. Kroll, et al.
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
Blood, June 15, 2005; 105(12): 4576 - 4582.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. R. Haugen
Patients with Differentiated Thyroid Carcinoma Benefit from Radioiodine Remnant Ablation
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3665 - 3667.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1993 by The Endocrine Society